BVXP Stock Overview
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£31.30|
|52 Week High||UK£45.49|
|52 Week Low||UK£30.00|
|1 Month Change||-6.57%|
|3 Month Change||-14.83%|
|1 Year Change||-29.66%|
|3 Year Change||-0.63%|
|5 Year Change||119.65%|
|Change since IPO||1,505.13%|
Recent News & Updates
Should Bioventix PLC (LON:BVXP) Be Part Of Your Dividend Portfolio?
Is Bioventix PLC ( LON:BVXP ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings...
Is Now The Time To Put Bioventix (LON:BVXP) On Your Watchlist?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
What Does Bioventix's (LON:BVXP) CEO Pay Reveal?
The CEO of Bioventix PLC ( LON:BVXP ) is Peter Harrison, and this article examines the executive's compensation against...
|BVXP||GB Biotechs||GB Market|
Return vs Industry: BVXP underperformed the UK Biotechs industry which returned -14.6% over the past year.
Return vs Market: BVXP underperformed the UK Market which returned 8.7% over the past year.
|BVXP Average Weekly Movement||4.0%|
|Biotechs Industry Average Movement||6.5%|
|Market Average Movement||5.0%|
|10% most volatile stocks in GB Market||10.7%|
|10% least volatile stocks in GB Market||2.5%|
Stable Share Price: BVXP is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BVXP's weekly volatility (4%) has been stable over the past year.
About the Company
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services.
Bioventix Fundamentals Summary
|BVXP fundamental statistics|
Is BVXP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BVXP income statement (TTM)|
|Cost of Revenue||UK£817.45k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.29|
|Net Profit Margin||61.58%|
How did BVXP perform over the long term?See historical performance and comparison
4.6%Current Dividend Yield
Is Bioventix undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BVXP (£31.3) is trading above our estimate of fair value (£26.83)
Significantly Below Fair Value: BVXP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BVXP is good value based on its PE Ratio (24.2x) compared to the UK Biotechs industry average (44.5x).
PE vs Market: BVXP is poor value based on its PE Ratio (24.2x) compared to the UK market (19.1x).
Price to Earnings Growth Ratio
PEG Ratio: BVXP's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: BVXP is overvalued based on its PB Ratio (13.8x) compared to the GB Biotechs industry average (5.6x).
How is Bioventix forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BVXP's earnings are forecast to decline over the next 3 years (-1% per year).
Earnings vs Market: BVXP's earnings are forecast to decline over the next 3 years (-1% per year).
High Growth Earnings: BVXP's earnings are forecast to decline over the next 3 years.
Revenue vs Market: BVXP's revenue (0.8% per year) is forecast to grow slower than the UK market (4.9% per year).
High Growth Revenue: BVXP's revenue (0.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BVXP's Return on Equity is forecast to be very high in 3 years time (58.8%).
How has Bioventix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BVXP has high quality earnings.
Growing Profit Margin: BVXP's current net profit margins (61.6%) are lower than last year (69.8%).
Past Earnings Growth Analysis
Earnings Trend: BVXP's earnings have grown by 11.4% per year over the past 5 years.
Accelerating Growth: BVXP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BVXP had negative earnings growth (-6.5%) over the past year, making it difficult to compare to the Biotechs industry average (50.7%).
Return on Equity
High ROE: BVXP's Return on Equity (56.9%) is considered outstanding.
How is Bioventix's financial position?
Financial Position Analysis
Short Term Liabilities: BVXP's short term assets (£11.5M) exceed its short term liabilities (£1.0M).
Long Term Liabilities: BVXP's short term assets (£11.5M) exceed its long term liabilities (£78.1K).
Debt to Equity History and Analysis
Debt Level: BVXP is debt free.
Reducing Debt: BVXP has not had any debt for past 5 years.
Debt Coverage: BVXP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BVXP has no debt, therefore coverage of interest payments is not a concern.
What is Bioventix current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BVXP's dividend (4.57%) is higher than the bottom 25% of dividend payers in the UK market (1.37%).
High Dividend: BVXP's dividend (4.57%) is in the top 25% of dividend payers in the UK market (4.04%)
Stability and Growth of Payments
Stable Dividend: BVXP's dividends per share have been stable in the past 10 years.
Growing Dividend: BVXP's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (81.3%), BVXP's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BVXP's dividends in 3 years are not forecast to be well covered by earnings (96.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Peter Harrison (63 yo)
Mr. Peter John Harrison, MA, serves as the Chief Executive Officer of Bioventix PLC. Mr. Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development a...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD411.71K) is about average for companies of similar size in the UK market ($USD573.76K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Experienced Board: BVXP's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BVXP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bioventix PLC's employee growth, exchange listings and data sources
- Name: Bioventix PLC
- Ticker: BVXP
- Exchange: AIM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£163.052m
- Shares outstanding: 5.21m
- Website: https://www.bioventix.com
Number of Employees
- Bioventix PLC
- 27–28 Eastcastle Street
- Greater London
- W1W 8DH
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 21:22|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.